Concord Biotech: Q2 Results Approved, Targets Cell/Gene Therapy Acquisition

Concord Biotech Limited's board of directors met on November 13, 2025, to approve its unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2025. The company reported revenue of Rs. 451.1 crores for H1 FY26. PAT stood at Rs. 107 crores for H1 FY26, with PAT Margin at 23.7%.

In a significant strategic move, the board approved the acquisition of 100% equity share capital of M/s Celliimune Biotech Private Limited, following an Audit Committee recommendation. This investment, aimed at expanding into the cell and gene therapy segment, underscores Concord Biotech's commitment to innovation in cancer treatment. Additionally, the board sanctioned an investment of up to Rs. 10 Crores in a Captive Hybrid Solar Power Project for its Limbasi Plant.

The unaudited financial results for both standalone and consolidated entities, along with the Limited Review Report from M/s. BSR & Co. LLP, were enclosed with the regulatory filing.